HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) rose more than 8% in the afternoon after recently reaching a cooperation with Whitehawk to launch five dual-antibody ADC products overseas.
Bioasis Technologies-B (02315) rose by more than 8% in the afternoon, and as of the time of reporting, it had increased by 6.28%, priced at HKD 53.3, with a trading volume of HKD 52.4807 million.
Biocytogen Pharmaceuticals-B (02315) rose more than 8% in the afternoon, and as of the time of writing, it is up 6.28%, priced at HKD 53.3, with a trading volume of HKD 52.4807 million.
In recent news, Biocytogen Pharmaceuticals has reached a global strategic cooperation agreement with Whitehawk Therapeutics, covering multiple dual-specific antibody-drug conjugate (BsADC) development projects. The two parties will jointly advance a new generation of therapeutic product pipelines. The time from the official start of cooperation to the completion of the agreement was only about four months, significantly faster than similar projects in the industry.
It is reported that Whitehawk will evaluate five dual-specific antibodies provided by Biocytogen Pharmaceuticals and has the right to choose to advance any resulting ADC candidate drugs into its development pipeline. Biocytogen Pharmaceuticals will receive a certain amount of upfront payment and potential milestone payments. The CEO of Whitehawk stated that the company expects to submit new ADC clinical trial applications (IND) within the next 12 to 24 months.
Related Articles
Morgan Stanley: Maintains "Overweight" rating on XIAOMI-W (01810); expects average smartphone selling price to hit a new high in the second quarter.
HK Stock Market Move | SMC ELECTRIC (02381) saw a decline of over 12%, with a discount of approximately 65.63% in its general offer, and is expected to turn from a profit to a loss in the first half of the year.
HK Stock Market Move | HENLIUS (02696) surged over 7% in the afternoon, with data on HLX43 for thymic squamous cell carcinoma and research results related to H drug for lung cancer set to be unveiled soon.
Morgan Stanley: Maintains "Overweight" rating on XIAOMI-W (01810); expects average smartphone selling price to hit a new high in the second quarter.
HK Stock Market Move | SMC ELECTRIC (02381) saw a decline of over 12%, with a discount of approximately 65.63% in its general offer, and is expected to turn from a profit to a loss in the first half of the year.
HK Stock Market Move | HENLIUS (02696) surged over 7% in the afternoon, with data on HLX43 for thymic squamous cell carcinoma and research results related to H drug for lung cancer set to be unveiled soon.
RECOMMEND
